Salt Lake City, UT, May 1, 2019 – LifeVantage (Nasdaq:LFVN) has launched its third
European market in the past eight months, adding Ireland to its slate this week.
With select LifeVantage products having been offered in Ireland for approximately a year
as part of the company’s Global Customer Acquisition Program, the country has already
distinguished itself as a viable market.
“Ireland already has a solid base of customers who love our products and has proven
itself a successful customer market in a relatively short period of time, so opening it up
for distributor enrollments is the next natural progression,” said LifeVantage Chief Sales
Officer Justin Rose. “We’re excited about Ireland’s prospects as our newest market.”
The following products are available in Ireland: Protandim Nrf2 Synergizer® supplement,
Omega+ fish oil supplement, Pro+ probiotic supplement, TrueScience® Beauty System,
TrueScience Facial Cleanser, TrueScience Perfecting Lotion, TrueScience Eye Serum,
TrueScience Anti-Aging Cream, and TrueScience Hand Cream. Protandim Nrf2
Synergizer® supplement is scheduled to be available in June.
LifeVantage has operated in the United Kingdom, including Northern Ireland, since 2016
and also has a European presence in Germany, Netherlands, Austria, and Spain, in
addition to Ireland.
“The opening of Ireland is something that has been highly anticipated among many of
our leaders in the UK in particular, and we expect it to be a productive asset in our larger
European strategy,” said LifeVantage CEO Darren Jensen. “We’re excited to take this
next step and grow our biohacking community in a part of the world that is key to our
success."
The company anticipates further expansion in Europe to support growth in the region,
including in Belgium, which is currently scheduled for launch next month. Select
LifeVantage products are currently available in Belgium on a not-for-resale basis as part
of the same customer program.
With the addition of Ireland, LifeVantage now serves 14 markets in North America,
Europe, Australia, and Asia.
About LifeVantage
LifeVantage Corporation (Nasdaq:LFVN) is a pioneer in Nutrigenomics – a new science
dedicated to biohacking the human aging code. The company is engaged in the
identification, research, development, and distribution of advanced nutraceutical dietary
supplements and skin and hair care products, including Protandim®, a line of
scientifically-validated dietary supplements; TrueScience® Beauty and Hair Care Systems;
Petandim™ for Dogs, a companion pet supplement formulated to combat oxidative stress
in dogs; Axio® Smart Energy Drink mixes; PhysIQ™, a Smart Weight Management System;
and Omega+, a 3-in-1 fish oil supplement. LifeVantage was founded in 2003 and is
headquartered in Salt Lake City, Utah. For more information, visit www.lifevantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions
reflecting optimism, satisfaction or disappointment with current prospects, as well as
words such as “believe”, “hopes”, “intends”, “estimates”, “expects”, “projects”, “plans”,
“anticipates”, “look forward to”, “goal”, “may be”, and variations thereof, identify forward-
looking statements, but their absence does not mean that a statement is not forward-
looking. Examples of forward-looking statements include, but are not limited to,
statements we make regarding our future growth and projected success in certain
markets. Such forward-looking statements are not guarantees of performance and the
Company’s actual results could differ materially from those contained in such statements.
These forward-looking statements are based on the Company’s current expectations and
beliefs concerning future events affecting the Company and involve known and unknown
risks and uncertainties that may cause the Company’s actual results or outcomes to be
materially different from those anticipated and discussed herein. These risks and
uncertainties include, among others, those discussed in greater detail in the Company’s
Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q under
the caption “Risk Factors,” and in other documents filed by the Company from time to
time with the Securities and Exchange Commission. The Company cautions investors not
to place undue reliance on the forward-looking statements contained in this document.
All forward-looking statements are based on information currently available to the
Company on the date hereof, and the Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or circumstances after the
date of this document, except as required by law.
